Recon: Drugmakers launch $1B antibiotic development fund; Moderna taps Rovi to supply coronavirus vaccine outside US

• In race to bring vaccine to market, big pharma struggles to protect its intellectual property rights (CNBC)
• Who Gets a Vaccine First? US Considers Race in Coronavirus Plans (NYTimes)
• Grave Shortages of Protective Gear Flare Again as Covid Cases Surge (NYTimes)
• Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light (Fierce) (Press)
• Drug Derived From Plasma of Covid-19 Patients to Be Tested as Preventive Measure (WSJ)
• Merck expands Zymeworks antibody alliance, adding close to $900M in milestones (Endpoints)
• The home run count: The $100M+ mega-round boom in biotech inspired a $7.3B feeding frenzy — so far this year (Endpoints)

• Pharma industry commits $1bn to fight drug-resistant superbugs (Financial Times) (Washington Post) (Press)
• Moderna in Pact With Rovi to Supply Virus Vaccine Outside US (Bloomberg)
• Independent evaluation of global COVID-19 response announced (WHO)
• Gilead to deliver more remdesivir to Europe from autumn: WiWo (Reuters)
• Sanofi pays $150M upfront, $2B in biobucks to tap protein degrader biotech Kymera (Fierce) (Endpoints)
• Indian Company Starts Mass-Producing Coronavirus Vaccines Before Trials (NPR)

• Study of 17 Million Identifies Crucial Risk Factors for Coronavirus Deaths (NYTimes)
• A flawed Covid-19 study gets the White House’s attention — and the FDA may pay the price (STAT)
• The first round of Covid-19 vaccines is ‘highly unlikely to be a magic bullet,’ Medicago CEO says (STAT)
• States with severe coronavirus outbreaks should ‘seriously look at shutting down,’ Dr. Fauci says (CNBC)
• ‘People can’t ignore it anymore’: Across the country, minorities hit hardest by pandemic (Politico)
• Oxford researchers develop portable COVID-19 test costing less than $25 (Fierce)
• Providers, insurers back ad campaign urging patients to stop 'medical distancing' (BioPharmaDive)
• Coronavirus (COVID-19) Update: Daily Roundup July 8, 2020 (FDA)

• Shingles Vaccination Rate Soars But Leaves Many Behind (KHN)
• A new study points to $6.5B in public support building foundation of remdesivir. Should that be reflected in the price? (Endpoints)
• After psilocybin and ketamine, a new biotech comes along developing a drug Scott Gottlieb fought (Endpoints)
• Baloxavir for Postexposure Prophylaxis against Influenza in Households (NEJM)
• Mylan and Pfizer roll out tricolor branding for their giant generics combo, Viatris (Fierce)
• Drug Companies Reserving Seat for Patent Lawyers at Deal Table (Bloomberg)
• Another biotech IPO set-up? Multinational biotech leaps from round to round, scooping up cash at a blistering pace (Endpoints)
• Forbion spotlights late-stage plays, carves out new €250M growth fund (Endpoints)
• Stanford star oncology scientist Ed Engleman helped create the immunotherapy field. Now he wants to shake up neurodegeneration R&D (Endpoints)
• The Cost Of ‘Stacking’ Orphan Indications And A Case For Reform (Pink Sheet)
• Urgent action required to revive the Indian pharma ancillary industry: IPA (Economic Times)
• LEO Pharma announces U.S. Food and Drug Administration (FDA) acceptance of Biologics License Application (BLA) for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis (Press)

• Technology Bridges the Gap to Better Sight (NYTimes)
• Newest Medtronic implantable heart monitor gets FDA nod as remote device features proliferate (MedtechDive)
• Intersect ENT stock jumps on report of potential Medtronic takeover (MedtechDive)
• Philips wins $100M tele-ICU contract from VA (MedtechDive)
• Q2 previews show coronavirus diagnostics bump for Thermo Fisher, Quidel, GenMark (MedtechDive)
• FDA clears Nonin's hand-held carbon monoxide poisoning meter for first responders (Fierce)
• Baxter Announces U.S. FDA Clearance of Altapore Shape Bioactive Bone Graft for Use in Surgery (Press)
• FDA clears Therapixel’s Mammoscreen (MassDevice)
• Medtronic, Tandem Diabetes Care bury the hatchet on potential IP disputes (MassDevice)

• Pompeo: State Department 'will work with Congress' on pledged funding to WHO (The Hill)
• One Federal Agency Was Suing Him for Fraud. Another Paid His Company Millions for Masks. (ProPublica)
• AbbVie may face fewer wrinkles after judge suggests a 10-year ban on a Botox rival (STAT)
• ALJ Recommends Exclusion in Botox Trade Secret Case (Big Molecule Watch)
• Ohio Ruling Adds To Insurance Uncertainty For Opioid Suits (Law360)
• Wholesaler Dropped As Lead In ADHD Drug Antitrust Suit (Law360)